Skip to Main Content

Below you will find tools to help you calculate dosing for your patients, as well as reconstitution and dispensing information that pharmacists may find useful. There are also several resources and links for you to share with patients, parents, and caregivers to help them access information about ADHD, ADHD support programs, and Tris Pharma products.

Dosing calculatorscaret
Info for pharmacistscaret
Co-pay offerscaret
ADHD resourcescaret
ADHD community resourcescaret
Pharmacy locatorcaret

Dosing Calculators

DYANAVEL XR Liquid amphetamine extended-release oral suspension 2.5 mg/mL Logo/mL Logo
Dosing for DYANAVEL XR
oral suspension caret

Information for Pharmacists

Dispensing

DYANAVEL XR (amphetamine) tablet is available in a 5-mg scored tablet and 10-, 15-, and 20-mg unscored tablets that can be taken with or without food. For full pharmacist instructions for dispensing and storage, see Full Prescribing Information for DYANAVEL XR.

Dosing for DYANAVEL XR
tablet caret
Co-pay card caret
DYANAVEL XR Tablet amphetamine extended-release tablets 5mg, 10mg, 15mg, 20mg Logo

Dispensing

DYANAVEL XR (amphetamine) oral suspension is supplied as a light beige to tan viscous oral suspension. DYANAVEL XR oral suspension is already flavored; DO NOT add any flavoring. For full pharmacist instructions for reconstitution, preparation, dispensing, and storage, see Full Prescribing Information for DYANAVEL XR.

Dosing for DYANAVEL XR
oral suspension caret
Dosing calculator for DYANAVEL XR
oral suspension caret
Co-pay card caret
DYANAVEL XR Liquid amphetamine extended-release oral suspension 2.5 mg/mL Logo/mL Logo

Co-pay Offers

Help Your Patients Save On Tris ADHD Products Money Sign Icon

Help your patients save on Tris ADHD products.

Learn more caret

ADHD Resources to Download

Pediatric patients and caregivers

Tris ADHD DXRT Patient Brochure
DYANAVEL XR Tablet Patient Brochure

Download this guide for your patients so that they can learn more about ADHD, DYANAVEL XR tablet, support, and resources.

Tris ADHD DXR OS Patient Brochure
DYANAVEL XR Oral Suspension Patient Brochure

Download this guide for your patients so that they can learn more about ADHD, DYANAVEL XR oral suspension, support, and resources.

ADHD Community Resources

AAP/Healthy Children

Healthy Children is the official American Academy of Pediatrics (AAP) website for parents, hosting a variety of articles that address common questions and issues in diagnosing and treating ADHD in children. Search for ADHD at healthychildren.org for information about topics like:

  • ADHD Myths and Misconceptions
  • ADHD Medications Daily Routines
  • Causes of ADHD: What We Know Today

ADDA

The Attention Deficit Disorder Association (ADDA) is the world’s leading adult ADHD association, dedicated to helping adults with ADHD lead better lives. Visit add.org to learn more about:

  • Adult ADHD Self-Screening Questionnaire
  • Virtual Peer Support Groups
  • Educational Resources

ADDitude Magazine

Online magazine for caregivers of children with attention deficit disorders. Visit additudemag.com to learn more.

CHADD

Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) is a nationally recognized nonprofit organization providing education, advocacy, and support for individuals with ADHD. Visit chadd.org

CDC

The Centers for Disease Control and Prevention (CDC) has published facts, research, statistics, and a wide array of other tools for parents to educate themselves about ADHD. Visit cdc.gov/ncbddd/adhd to learn more.

NIMH

The National Institute of Mental Health (NIMH), a component of the US Department of Health and Human Services, provides in-depth information and resources on ADHD diagnosis and treatment at nimh.nih.gov.

Pharmacy Locator

To find a nearby pharmacy with Tris ADHD products in stock, search pharmacies by ZIP code below.

Search by ZIP code

Sign up to receive additional information and product updates, or to request a representative.

ADHD, Attention Deficit Hyperactivity Disorder; CNS, central nervous system.

Request more information about DYANAVEL XR

Click below to sign up to receive more information about DYANAVEL XR.

You can also request a visit from a Tris Pharma representative.

IMPORTANT SAFETY INFORMATION

isi open close button

WARNING: ABUSE, MISUSE, AND ADDICTION

DYANAVEL XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DYANAVEL XR, can result in overdose and death. Before prescribing DYANAVEL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.

IMPORTANT SAFETY INFORMATION

INDICATION

DYANAVEL® XR (amphetamine) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

WARNING: ABUSE, MISUSE, AND ADDICTION

DYANAVEL XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DYANAVEL XR, can result in overdose and death. Before prescribing DYANAVEL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction..

  • DYANAVEL XR is contraindicated:
    • in patients known to be hypersensitive to amphetamine, or other components of DYANAVEL XR. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported with other amphetamines.
    • in patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of increased risk of hypertensive crisis.
  • Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD doses. Serious cardiovascular effects with overdose may precipitate sudden cardiac death. Prior to treating patients with DYANAVEL XR, assess for the presence of cardiac disease. Avoid DYANAVEL XR use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during DYANAVEL XR treatment.
  • CNS stimulants cause increase in blood pressure (mean increase about 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Monitor all patients for potential tachycardia and hypertension.
  • Use of CNS stimulants may cause exacerbation of pre-existing psychosis and may induce a manic or mixed episode in patients with bipolar disorder. In patients without prior history of psychotic illness or mania, CNS stimulants may cause new psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) at the recommended dosage. Prior to initiating DYANAVEL XR treatment, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing DYANAVEL XR.
  • CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients with ADHD; monitor weight and height during treatment with DYANAVEL XR. Treatment may need to be interrupted in children not growing as expected.
  • CNS stimulants, including DYANAVEL XR, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for DYANAVEL XR-treated patients who develop signs or symptoms of peripheral vasculopathy.
  • Serotonin syndrome risk is increased when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), MAOIs, and during overdosage situations. If it occurs, discontinue DYANAVEL XR and any concomitant serotonergic agents immediately, and initiate supportive treatment.
  • CNS stimulants, including amphetamine, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported. Before initiating DYANAVEL XR, assess the family history and clinically evaluate patients for tics or Tourette’s syndrome. Regularly monitor DYANAVEL XR-treated patients for the emergence or worsening of tics or Tourette’s syndrome and discontinue treatment if clinically appropriate.
  • Most common adverse reactions observed with amphetamine products: dry mouth, anorexia, weight loss, abdominal pain, nausea, insomnia, restlessness, emotional lability, dizziness, and tachycardia. Based on limited experience with DYANAVEL XR in controlled trials, the adverse reaction profile of DYANAVEL XR appears similar to other amphetamine extended-release products. The most common (≥2% in the DYANAVEL XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 108 patients with ADHD (aged 6 to 12 years) were: epistaxis (DYANAVEL XR 4%, placebo 0%), allergic rhinitis (4%, 0%) and upper abdominal pain (4%, 2%).
  • DYANAVEL XR use during pregnancy may cause fetal harm. To monitor pregnancy outcomes in women exposed to DYANAVEL XR during pregnancy, healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/.
  • Because of the potential for serious adverse reactions in a breastfed infant, breastfeeding is not recommended during treatment with DYANAVEL XR.
  • To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc. at (732) 940-0358 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information for DYANAVEL XR including Boxed Warning regarding Abuse, Misuse, and Addiction.

You are now leaving this website

You are about to leave DYANAVELXRhcp.com and enter a website operated by a third party. Would like to continue?

Yes
Interested in more information?

To learn more about Tris ADHD products, or to speak to a representative, please click below.

"